NCT06997939View on ClinicalTrials.gov

Autologous Bone Marrow Mesenchymal Stem Cell Therapy for Ischemic Stroke

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2027

Conditions
Ischemic Stroke
Interventions
BIOLOGICAL

ABMSC

Autologous bone marrow-derived mesenchymal stem cells administered via Ommaya reservoir；2.0\*10\^7 cell/dose

BIOLOGICAL

ABMSC

Autologous bone marrow-derived mesenchymal stem cells via intra-arterial route；Low-dose group; 2.5\*10\^6 cell/dose

BIOLOGICAL

ABMSC

Autologous bone marrow-derived mesenchymal stem cells via intra-arterial route；High-dose group; 1.0\*10\^7 cell/dose

Trial Locations (1)

226000

Affiliated Hospital of Nantong University, Nantong

All Listed Sponsors
collaborator

Nantong Shengyuan Stem Cell Techology Co., Ltd

UNKNOWN

lead

Affiliated Hospital of Nantong University

OTHER

NCT06997939 - Autologous Bone Marrow Mesenchymal Stem Cell Therapy for Ischemic Stroke | Biotech Hunter | Biotech Hunter